BioAgilytix, a global contract research organization focused on supporting pharmaceutical and biotech partners in all phases of drug development, completed the acquisition of 360biolabs, a contract service organisation providing specialist expertise and laboratory services for the development of new therapeutics, vaccines and diagnostics in a quality-assured environment. Financial terms were not disclosed. "360biolabs' leadership position in virology and immunology, plus their small molecule capabilities and locations in Melbourne and Brisbane, help make BioAgilytix an end-to-end bioanalytical force dedicated to helping generate new innovations and life-changing therapeutics for patients around the world," Jim Datin, BioAgilytix President and CEO.